K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 7, 2016, Pages 831-842

  Nussinov, Ruth ^a,b   Muratcioglu, Serena ^c   Tsai, Chung Jung ^a   Jang, Hyunbum ^a   Gursoy, Attila ^c   Keskin, Ozlem ^c  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c KOÇ UNIVERSITY   (Turkey)

Author keywords

allosteric drugs; calcium; calmodulin; colorectal cancer; K Ras dimers; KRAS; KRAS4A; KRAS4B; lung cancer; orthosteric drugs; pancreatic cancer; pancreatic ductal adenocarcinomas (PDAC); small molecule drug

Indexed keywords

CALCIUM; CALCIUM ION; CALMODULIN; K RAS PROTEIN; K RAS4B PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN P21;

ADENOCARCINOMA; CANCER TISSUE; CLINICAL FEATURE; COLORECTAL CANCER; CRYSTAL STRUCTURE; DOWN REGULATION; ELECTRON MICROSCOPY; GENE MUTATION; HUMAN; LUNG CANCER; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CALMODULIN; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84957920709     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1135131     Document Type: Review

References (139)

1. G.Kozak, F.F.Blanco, J.R.Brody Novel targets in pancreatic cancer research. Semin Oncol. 2015;42:177–187.• This paper discusses the key genetic and non-genetic mechanisms responsible for PDA initiation and progression. Based on these mechanisms it suggests novel therapeutic targets in PDA.
2. A.D.Cox, C.J.Der, M.R.Philips Targeting RAS membrane association: back to the future for anti-ras drug discovery?. Clin Cancer Res. 2015;21:1819–1827.
3. J.Downward. RAS synthetic lethal screens revisited: still seeking the elusive prize?. Clin Cancer Res. 2015;21:1802–1809.
4. E.G.Chiorean, A.L.Coveler. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529–3545.
5. G.M.Heestand, R.Kurzrock. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 2015;6:4553–4561.
6. H.Ebi, A.C.Faber, J.A.Engelman, et al. Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci. 2014;105:499–505.
7. A.D.Cox, S.W.Fesik, A.C.Kimmelman, et al. Drugging the undruggable RAS: Mission possible?. Nat Rev Drug Discov. 2014;13:828–851.• The authors summarize the progress and the promise of five key approaches to target Ras: (1) direct inhibitors of RAS; (2) RAS membrane association; (3) targeting RAS downstream effector signalling; (4) synthetic lethal interactors of mutant RAS; and (5) RAS-mediated changes in cell metabolism.
8. Q.Sun, J.Phan, A.R.Friberg, et al. A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. J Biomol NMR. 2014;60:11–14.
9. D.B.Kokh, S.Richter, S.Henrich, et al. TRAPP: a tool for analysis of transient binding pockets in proteins. J Chem Inf Model. 2013;53:1235–1252.
10. A.Bernini, L.Henrici De Angelis, E.Morandi, et al Searching for protein binding sites from Molecular Dynamics simulations and paramagnetic fragment-based NMR studies. Biochim Biophys Acta. 2014;1844:561–566.
11. I.Kufareva, Y.-C.Chen, A.V.Ilatovskiy, et al. Compound activity prediction using models of binding pockets or ligand properties in 3D. Curr Top Med Chem. 2012;12:1869–1882.
12. P.A.Hubbard, C.L.Moody, R.Murali. Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Front Physiol. 2014;5:478.• The authors focus on the recent advances and merits of developing allosteric drugs targeting Ras and the PI3K/AKT/mTOR pathway.
13. J.M.Ostrem, U.Peters, M.L.Sos, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–551.•• Here the authors describe the design of an a covalent allosteric drug to target K-Ras(G12C) to control GTP affinity and effector interactions. This is the first such design.
14. Y.Wang, C.E.Kaiser, B.Frett, et al. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem. 2013;56:5219–5230.
15. R.Nussinov, S.Muratcioglu, C.-J.Tsai, et al. The key role of calmodulin in KRAS-driven adenocarcinomas. Mol Cancer Res. 2015;13:1265–1273.•• Here the authors propose an explanation for the challenging question of how calmodulin acts to uniquely stimulate oncogenic K-Ras action rather than other Ras isoforms, and do so in mechanistic detail. Based on this mechanistic underpinning they further suggest a drug target.
16. M.W.Berchtold, A.Villalobo. The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. Biochim Biophys Acta. 2014;1843:398–435.•• A very useful review of the action of CaM and CaM-dependent signaling systems in the control of vertebrate cell proliferation, programmed cell death and autophagy. The authors highlight the importance of CaM and interconnected CaM-regulated systems for the physiology of cancer cells including tumor stem cells, and processes required for tumor progression such as growth, tumor-associated angiogenesis and metastasis are highlighted. It also discusses the potential targeting of CaM-dependent signaling processes for therapeutic use.
17. B.W.Benham-Pyle, B.L.Pruitt, W.J.Nelson. Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and β-catenin activation to drive cell cycle entry. Science. 2015;348:1024–1027.•• In this paper the authors showed that mechanical strain applied to quiescent epithelial cells induced rapid cell cycle reentry. Of particular importance, this cell cycle effect was mediated by accumulation and transcriptional activity of Yap1 followed by β-catenin. Inhibition of Yap1- and β-catenin-mediated transcription blocked cell cycle reentry and progression through G1 into S phase, respectively. Maintenance of quiescence, Yap1 nuclear exclusion, and β-catenin transcriptional responses to mechanical strain required E-cadherin extracellular engagement.
18. A.Kapoor, W.Yao, H.Ying, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014;158:185–197.
19. R.Nussinov, C.-J.Tsai, C.Mattos. ‘Pathway drug cocktail’: targeting Ras signaling based on structural pathways. Trends Mol Med. 2013;19:695–704.
20. H.Jubb, T.L.Blundell, D.B.Ascher. Flexibility and small pockets at protein-protein interfaces: New insights into druggability. Prog Biophys Mol Biol. 2015;119:2–9.
21. A.P.Higueruelo, H.Jubb, T.L.Blundell. Protein-protein interactions as druggable targets: recent technological advances. Curr Opin Pharmacol. 2013;13:791–796.
22. R.Nussinov, C.-J.Tsai. Unraveling structural mechanisms of allosteric drug action. Trends Pharmacol Sci. 2014;35:256–264.•• This paper provides a novel mechanistic insight into the mode of action of allosteric drugs.
23. G.Kar, O.Keskin, A.Gursoy, et al. Allostery and population shift in drug discovery. Curr Opin Pharmacol. 2010;10:715–722.
24. R.Nussinov, C.-J.Tsai. The different ways through which specificity works in orthosteric and allosteric drugs. Curr Pharm Des. 2012;18:1311–1316.
25. R.Nussinov, C.-J.Tsai. Allostery in disease and in drug discovery. Cell. 2013;153:293–305.
26. R.Nussinov, C.-J.Tsai. The design of covalent allosteric drugs. Annu Rev Pharmacol Toxicol. 2015;55:249–267.
27. C.Sheridan. Evading inhibitory constraints - destabilizing p110alpha/p85alpha interactions. Febs J. 2015;282:3525–3527.
28. B.Vanhaesebroeck, S.J.Leevers, K.Ahmadi, et al Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 2001;70:535–602.
29. O.Vadas, J.E.Burke, X.Zhang, et al. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal. 2011;4:re2.•• Here the authors provide unique insight into the structural basis for activation and inhibition of class I phosphoinositide 3-kinases.
30. J.L.Joyal, D.J.Burks, S.Pons, et al Calmodulin activates phosphatidylinositol 3-kinase. J Biol Chem. 1997;272:28183–28186.
31. Y.Xu, N.Li, R.Xiang, et al. Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci. 2014;39:268–276.• The authors provide a useful overview of scenesence, focusing on the roles of p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.
32. D.Mandelker, S.B.Gabelli, O.Schmidt-Kittler, et al A frequent kinase domain mutation that changes the interaction between PI3K alpha and the membrane. Proc Natl Acad Sci U S A. 2009;106:16996–17001.
33. S.Gabelli, I.Echeverria, M.Alexander, et al. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects. Biophys Rev. 2014;6:89–95.
34. J.E.Burke, O.Perisic, G.R.Masson, et al. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 alpha (PIK3CA). Proc Natl Acad Sci U S A. 2012;109:15259–15264.•• In this paper the authors elucidate a unifying mechanism in which diverse PIK3CA mutations stimulate lipid kinase activity by facilitating allosteric motions required for catalysis on membranes.
35. B.Ma, C.-J.Tsai, T.Haliloglu, et al. Dynamic allostery: linkers are not merely flexible. Structure. 2011;19:907–917.
36. L.Zhao, P.K.Vogt. Class IPI3K in oncogenic cellular transformation. Oncogene. 2008;27:5486–5496.
37. J.Downward. Ras signalling and apoptosis. Curr Opin Genet Dev. 1998;8:49–54.
38. R.Khosravi-Far, S.Campbell, K.L.Rossman, et al. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res. 1998;72:57–107.
39. C.Carta, F.Pantaleoni, G.Bocchinfuso, et al Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet. 2006;79:129–135.
40. S.Pells, M.Divjak, P.Romanowski, et al. Developmentally-regulated expression of murine K-ras isoforms. Oncogene. 1997;15:1781–1786.
41. S.Roy, R.Luetterforst, A.Harding, et al. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol. 1999;1:98–105.
42. J.Yan, S.Roy, A.Apolloni, et al. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 1998;273:24052–24056.
43. L.Johnson, D.Greenbaum, K.Cichowski, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 1997;11:2468–2481.
44. L.M.Esteban, C.Vicario-Abejon, P.Fernandez-Salguero, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001;21:1444–1452.
45. J.H.Jackson, J.W.Li, J.E.Buss, et al. Polylysine domain of K-ras 4B protein is crucial for malignant transformation. Proc Natl Acad Sci U S A. 1994;91:12730–12734.
46. S.J.Plowman, R.L.Berry, S.A.Bader, et al. K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J Exp Clin Cancer Res. 2006;25:259–267.
47. N.Normanno, S.Tejpar, F.Morgillo, et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6:519–527.
48. J.C.Stone. Regulation and function of the rasgrp family of ras activators in blood cells. Genes Cancer. 2011;2:320–334.
49. F.D.Tsai, M.S.Lopes, M.Zhou, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc Natl Acad Sci U S A. 2015;112:779–784.•• Here the authors show that K-Ras4A splice variant is widely expressed and can act in two distinct modes: K-Ras4B- and N-Ras-like. This is the first paper to analyze K-Ras4A in such depth, leading to unique insight into its action.
50. C.E.Patek, M.J.Arends, W.A.Wallace, et al. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp Cell Res. 2008;314:1105–1114.
51. J.Abubaker, P.Bavi, W.Al-Haqawi, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 2009;219:435–445.
52. E.Choy, V.K.Chiu, J.Silletti, et al. Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell. 1999;98:69–80.
53. J.F.Hancock, H.Paterson, C.J.Marshall. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell. 1990;63:133–139.
54. R.Nussinov, C.-J.Tsai, M.Chakrabarti, et al. A new view of Ras isoforms in cancers. Cancer Res. 2016;76:18–23.
55. E.Castellano, J.Downward. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011;2:261–274.
56. Y.Pylayeva-Gupta, E.Grabocka, D.Bar-Sagi. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–774.
57. E.Castellano, E.Santos. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011;2:216–231.
58. I.A.Prior, P.D.Lewis, C.Mattos. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457–2467.
59. D.P.Ryan, T.S.Hong, N.Bardeesy. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–1049.• A useful overview overview of pancreatic adenocarcinoma from the basic and clinical standpoints.
60. K.L.Bryant, J.D.Mancias, A.C.Kimmelman, et al. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91–100.• The authors provide a comprehensive and coherent description of the central role of oncogenic KRAS in controlling tumor metabolism by orchestrating multiple metabolic changes including stimulation of glucose uptake, differential channeling of glucose intermediates, reprogrammed glutamine metabolism, increased autophagy, and macropinocytosis. They also discuss how these may be applied to develop new PDAC treatments.
61. C.Guerra, A.J.Schuhmacher, M.Cañamero, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:291–302.
62. S.R.Hingorani, E.F.Petricoin, A.Maitra, et al Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–450.
63. J.Morris, S.C.Wang, M.Hebrok. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10:683–695.•• The authors provide a useful review of the roles of Hedgehog and Wnt signaling in K-Ras-driven pancreatic adenocarcinoma.
64. A.V.Pinho, I.Rooman, M.Reichert, et al. Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut. 2011;60:958–966.
65. B.Seidler, A.Schmidt, U.Mayr, et al. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A. 2008;105:10137–10142.
66. R.G.Amado, M.Wolf, M.Peeters, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634.
67. C.S.Karapetis, S.Khambata-Ford, D.J.Jonker, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765.
68. B.Vogelstein, E.R.Fearon, S.R.Hamilton, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532.
69. B.M.Ku, E.H.Jho, Y.H.Bae, et al. BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. Invest New Drugs. 2015;33:12–21.
70. S.Forbes, J.Clements, E.Dawson, et al. Cosmic 2005. Br J Cancer. 2006;94:318–322.
71. S.J.Abraham, R.P.Nolet, R.J.Calvert, et al. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Biochemistry. 2009;48:7575–7583.
72. D.R.Sauter, I.Novak, S.F.Pedersen, et al. ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC). Pflugers Arch. 2015;467:1495–1508.
73. Y.Chen, Y.Z.Zhang, Z.G.Zhou, et al. Identification of differently expressed genes in human colorectal adenocarcinoma. World J Gastroenterol. 2006;12:1025–1032.
74. G.X.Liu, H.F.Sheng, S.Wu. A study on the levels of calmodulin and DNA in human lung cancer cells. Br J Cancer. 1996;73:899–901.
75. S.Barry, T.Crnogorac-Jurcevic. S100P (S100 calcium binding protein P). Atlas Genet Cytogenet Oncol Haematol. 2009;13:429–431.
76. T.B.Deb, C.M.Coticchia, R.B.Dickson. Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells. J Biol Chem. 2004;279:38903–38911.
77. H.Yang, Q.Zhang, J.He, et al. Regulation of calcium signaling in lung cancer. J Thorac Dis. 2010;2:52–56.
78. Z.L.Chen, S.H.Zhao, Z.Wang, et al. Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer. Chin J Cancer. 2011;30:62–68.
79. S.Chai, X.Xu, Y.Wang, et al. Ca2+/calmodulin-dependent protein kinase IIgamma enhances stem-like traits and tumorigenicity of lung cancer cells. Oncotarget. 2015;6:16069–16083.
80. R.Nussinov, B.Ma, C.-J.Tsai. A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery. Biochim Biophys Acta. 2013;1834:820–829.
81. S.Eser, A.Schnieke, G.Schneider, et al. Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. 2014;111:817–822.
82. M.Hidalgo. New insights into pancreatic cancer biology. Ann Oncol: Official J Eur Soc Med Oncology/ESMO. 2012;23(Suppl 10):x135–8.
83. C.Feig, A.Gopinathan, A.Neesse, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266–4276.
84. K.E.Poruk, M.A.Firpo, S.J.Mulvihill. Screening for pancreatic cancer. Adv Surg. 2014;48:115–136.
85. R.Nussinov, C.-J.Tsai. ‘Latent drivers’ expand the cancer mutational landscape. Curr Opin Struct Biol. 2015;32:25–32.
86. R.H.Hruban, A.Maitra, M.Goggins. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008;1:306–316.
87. D.Matthaios, P.Zarogoulidis, I.Balgouranidou, et al. Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology. 2011;81:259–272.
88. M.I.Canto, R.H.Hruban, E.K.Fishman, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142:796–804. quiz e14-5
89. G.Feldmann, R.Beaty, R.H.Hruban, et al. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg. 2007;14:224–232.
90. S.Jones, X.Zhang, D.W.Parsons, et al Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.
91. A.V.Biankin, N.Waddell, K.S.Kassahn, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399–405.
92. S.R.Hustinx, L.M.Leoni, C.J.Yeo, et al. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Modern Pathol: Official J United States Canadian Acad Pathology, Inc. 2005;18:959–963.
93. H.Ying, A.C.Kimmelman, C.A.Lyssiotis, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656–670.
94. M.A.Collins, F.Bednar, Y.Zhang, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The. J Clin Investigation. 2012;122:639–653.
95. M.A.Collins, J.C.Brisset, Y.Zhang, et al. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One. 2012;7:e49707.
96. A.Singh, P.Greninger, D.Rhodes, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15:489–500.
97. N.Berndt, A.D.Hamilton, S.M.Sebti. Targeting protein prenylation for cancer therapy. Nat Rev Cancer. 2011;11:775–791.
98. W.R.Samore, C.S.Gondi. Brief overview of selected approaches in targeting pancreatic adenocarcinoma. Expert Opin Investig Drugs. 2014;23:793–807.• The authors provide a brief and focused description of current strategies to target pancreatic adenocarcinoma.
99. A.Kleger, L.Perkhofer, T.Seufferlein. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol: Official J Eur Soc Med Oncology/ESMO. 2014;25:1260–1270.
100. R.Maréchal, A.Demols, J.-L.Van Laethem. Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer. Drugs Aging. 2013;30:155–165.
101. A.Basseville, S.Bates, T.Fojo. Pancreatic cancer: targeting KRAS and the vitamin D receptor via microtubules. Nat Rev Clin Oncol. 2015;12:442–444.
102. J.A.Thissen, J.M.Gross, K.Subramanian, et al. Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking. J Biol Chem. 1997;272:30362–30370.
103. A.Apolloni, I.A.Prior, M.Lindsay, et al. H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol Cell Biol. 2000;20:2475–2487.
104. E.A.Collisson, A.Sadanandam, P.Olson, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–503.
105. D.D.Von Hoff, R.K.Ramanathan, M.J.Borad, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–4554.
106. M.S.Poruchynsky, E.Komlodi-Pasztor, S.Trostel, et al. Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci U S A. 2015;112:1571–1576.
107. V.Bhattacharjee, Y.Zhou, T.J.Yen. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle. 2014;13:3839–3856.
108. F.Skoulidis, L.A.Byers, L.Diao, et al. Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860–877.
109. A.Chang. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71:3–10.
110. T.Hida, Y.Ariyoshi, M.Kuwabara, et al. Glutathione S-transferase pi levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn J Clin Oncol. 1993;23:14–19.
111. M.Tiseo, L.Boni, A.Ardizzoni, Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?. J Clin Oncol. 2005;23:6276–6278. author reply 7-8
112. B.C.Giovanella, J.S.Stehlin, M.E.Wall, et al. DNA topoisomerase I–targeted chemotherapy of human colon cancer in xenografts. Science. 1989;246:1046–1048.
113. F.Kanzawa, Y.Sugimoto, K.Minato, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990;50:5919–5924.
114. A.Saleem, T.K.Edwards, Z.Rasheed, et al. Mechanisms of resistance to camptothecins. Ann N Y Acad Sci. 2000;922:46–55.
115. O.Afzal, S.Kumar, M.R.Haider, et al A review on anticancer potential of bioactive heterocycle quinoline. Eur J Med Chem. 2015;97:871–910.
116. Y.Ding, T.A.Nguyen. PQ1, a quinoline derivative, induces apoptosis in T47D breast cancer cells through activation of caspase-8 and caspase-9. Apoptosis. 2013;18:1071–1082.
117. M.Sedic, M.Poznic, P.Gehrig, et al. Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-alpha]quinoline in colon cancer cells depending on their p53 status. Mol Cancer Ther. 2008;7:2121–2132.
118. Y.Nakamura, S.Yogosawa, Y.Izutani, et al. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer. 2009;8:100.
119. C.Y.Liu, P.T.Wu, J.P.Wang, et al An indolylquinoline derivative promotes apoptosis in human lung cancer cells by impairing mitochondrial functions. Apoptosis. 2015;20:1471–1482.
120. G.Hrustanovic, V.Olivas, E.Pazarentzos, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21:1038–1047.
121. M.Shea, D.B.Costa, D.Rangachari. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2015. doi:10.1177/1753465815617871.
122. A.Pasini, A.Delmonte, A.Tesei, et al. Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. Drugs. 2015;75:1757–1771.
123. K.K.To, W.W.Leung, S.S.Ng. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res. 2015;338:222–231.
124. K.Marcus, C.Mattos. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects. Clin Cancer Res. 2015;21:1810–1818.
125. A.C.Kimmelman. Metabolic dependencies in RAS-driven cancers. Clin Cancer Res. 2015;21:1828–1834.
126. S.Lu, H.Jang, J.Zhang, et al. Inhibitors of Ras-SOS Interactions. ChemMedChem. 2015. DOI:10.1002/cmdc.201500481.
127. S.Muratcioglu, T.S.Chavan, B.C.Freed, et al. GTP-Dependent K-Ras Dimerization. Structure. 2015;23:1325–1335.
128. X.Nan, T.M.Tamguney, E.A.Collisson, et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A. 2015;112:7996–8001.
129. H.Jang, S.J.Abraham, T.S.Chavan, et al. Mechanisms of Membrane Binding of Small GTPase K-Ras4B Farnesylated Hypervariable Region. J Biol Chem. 2015;290:9465–9477.
130. T.S.Chavan, H.Jang, L.Khavrutskii, et al. High-affinity interaction of the K-Ras4B hypervariable region with the Ras active site. Biophys J. 2015;109:2602–2613.
131. H.Lavoie, M.Therrien. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16:281–298.
132. S.Lu, A.Banerjee, H.Jang, et al. GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site. J Biol Chem. 2015;290:28887–28900.
133. R.Gowthaman, S.A.Miller, S.A.Rogers, et al. DARC: mapping surface topography by ray-casting for effective virtual screening at protein interaction sites. J Med Chem. 2015. DOI:10.1021/acs.jmedchem.5b00150.
134. D.Bier, P.Thiel, J.Briels, et al. Stabilization of Protein-Protein Interactions in chemical biology and drug discovery. Prog Biophys Mol Biol. 2015;119:10–19.
135. A.J.Wilson. Helix mimetics: recent developments. Prog Biophys Mol Biol. 2015;119:33–40.
136. D.E.Scott, A.G.Coyne, A.Venkitaraman, et al Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases. ChemMedChem. 2015;10:296–303.
137. D.E.Scott, M.T.Ehebauer, T.Pukala, et al. Using a fragment-based approach to target protein-protein interactions. Chembiochem. 2013;14:332–342.
138. H.Jubb, A.P.Higueruelo, A.Winter, et al. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol Sci. 2012;33:241–248.
139. Z.Shen, B.Z.Stanger, D.M.Koepp. YAP regulates S-phase entry in endothelial cells. PLoS One. 2015;10:e0117522.•• In this work the authors observe that YAP is required for proliferation in endothelial cells but not HeLa cells. YAP is required for S-phase entry and its absence causes cells to accumulate in G1. These observations point to cell-cell contacts regulating cell-cycle via the Hippo/YAP1 and provide a key mechanism in promoting cell proliferation and survival.